Advertisement


Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

2014 ASH Annual Meeting

Advertisement

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.



Related Videos

Lymphoma

Bertrand Coiffier, MD, PhD, on Radiotherapy Plus R-CHOP in Localized Diffuse Large B-Cell Lymphoma

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393,

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289,

Leukemia

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,

Myelodysplastic Syndromes

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...

Lymphoma
Myelodysplastic Syndromes

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “...

Advertisement

Advertisement



Advertisement